- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Six complaints against AstraZeneca. Breaches found for a UK meeting treated as non-promotional (certification/PI and ‘cure’ claims) and for LinkedIn engagement promoting…
An anonymous employee complained that Otsuka UK webpages listed POM brand/generic names and indications. The Panel ruled the pages promoted POMs to…
Boehringer Ingelheim admitted that June 2019 MIMS carried a Spiolto Respimat full-page ad plus a double-sided bookmark insert, exceeding the two-page limit…
A UCB employee’s personal LinkedIn profile described work on Phase 3 axial spondyloarthropathy for bimekizumab. The Panel ruled this promoted an unlicensed…
Bristol-Myers Squibb admitted a promotional article misquoted 30‑month overall survival figures for intermediate/poor-risk aRCC by using ITT data. The online article was…
AstraZeneca admitted an employee re-tweeted positive clinical-trial-related posts about Forxiga and a Lynparza news tweet from a personal account. The Panel found…
Vifor’s corporate website displayed inverted triangle symbols in blue/grey/white (not black) on IV iron product pages and mixed public and HCP information…
A GP challenged an Eliquis leavepiece claiming no dose adjustment in mild/moderate renal impairment. The PMCPA found the page misleading versus the…
Following BBC criticism, the PMCPA assessed a Napp-sponsored New York meeting for UK pain specialists. The Panel found breaches relating to overseas…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.